CTIC NASDAQ
CTI BioPharma Corp.
1W: +0.2%
1M: +1.1%
3M: +111.4%
1Y: +52.3%
3Y: +615.8%
5Y: +80.7%
$9.10
Last traded 2023-06-23 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$54M
+0.0% ▲
5Y CAGR: +16.5%
Gross Profit
$50M
+31425.5% ▲
5Y CAGR: +15.3%
Operating Income
-$80M
+16.3% ▲
Net Income
-$91M
+8.6% ▲
EPS (Diluted)
$-0.79
+28.8% ▲
EBITDA
-$80M
+16.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $26M | $3M | $0 | $0 | $54M |
| YoY Growth | +4.5% | -87.3% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $879K | $0 | $4M | $161K | $4M |
| Gross Profit | $25M | $3M | -$4M | -$161K | $50M |
| Gross Margin | 96.7% | 100.0% | — | — | 93.5% |
| R&D Expenses | $36M | $24M | $26M | $39M | $37M |
| SG&A Expenses | $21M | $19M | $18M | $56M | $85M |
| Operating Expenses | $58M | $43M | $48M | $95M | $130M |
| Operating Income | -$33M | -$41M | -$48M | -$95M | -$80M |
| Operating Margin | -125.1% | -1217.1% | — | — | -147.9% |
| Interest Expense | $2M | $2M | $1M | $2M | $13M |
| Income Before Tax | -$29M | -$40M | -$52M | -$98M | -$93M |
| Tax Expense | $5M | $2M | $500K | $2M | -$2M |
| Net Income | -$29M | -$42M | -$53M | -$100M | -$91M |
| Net Margin | -111.5% | -1265.1% | — | — | -168.8% |
| EPS (Diluted) | $-0.52 | $-0.73 | $-0.74 | $-1.11 | $-0.79 |
| EBITDA | -$33M | -$37M | -$51M | -$95M | -$80M |
| Shares Outstanding | 56M | 58M | 71M | 90M | 115M |